Genomic alterations in human malignant glioma cells associate with the cell resistance to the combination treatment with tumor necrosis factor-related apoptosis-inducing ligand and chemotherapy - PubMed (original) (raw)
Genomic alterations in human malignant glioma cells associate with the cell resistance to the combination treatment with tumor necrosis factor-related apoptosis-inducing ligand and chemotherapy
Yueh-Chun Li et al. Clin Cancer Res. 2006.
Abstract
Purpose: Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is currently under clinical development as a cancer therapeutic agent. Many human malignant glioma cells, however, are resistant to TRAIL treatment. We, therefore, investigated the genomic alterations in TRAIL-resistant malignant glioma cells.
Experimental design: Seven glioma cell lines and two primary cultures were first analyzed for their sensitivity to TRAIL and chemotherapy and then examined for the genomic alterations in key TRAIL apoptotic genes by comparative genomic hybridization (CGH), G-banding/spectral karyotyping, and fluorescence in situ hybridization (FISH).
Results: CGH detected loss of the chromosomal regions that contain the following genes: 8p12-p23 (DR4 and DR5), 2q33-34 (caspase-8), 11q13.3 (FADD), 22q11.2 (Bid), and 12q24.1-q24.3 (Smac/DIABLO) in TRAIL-resistant cell lines. Spectral karyotyping showed numerical and structural aberrations involving the chromosomal regions harboring these genes. A combination of G-banding/spectral karyotyping and FISH further defined the loss or gain of gene copy of these genes and further showed the simultaneous loss of one copy of DR4/DR5, caspase-8, Bid, and Smac in two near-triploid cell lines that were resistant to the combination treatment with TRAIL and chemotherapy. Loss of the caspase-8 locus was also detected in a primary culture in correlation with the culture resistance to the combined TRAIL and chemotherapy treatment.
Conclusions: The study identifies chromosomal alterations in TRAIL apoptotic genes in the glioma cells that are resistant to the treatment with TRAIL and chemotherapy. These genetic alterations could be used to predict the responsiveness of malignant gliomas to TRAIL-based therapies in clinical treatment of the tumors.
Similar articles
- Epigenetic silencing of death receptor 4 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in gliomas.
Elias A, Siegelin MD, Steinmüller A, von Deimling A, Lass U, Korn B, Mueller W. Elias A, et al. Clin Cancer Res. 2009 Sep 1;15(17):5457-65. doi: 10.1158/1078-0432.CCR-09-1125. Epub 2009 Aug 25. Clin Cancer Res. 2009. PMID: 19706813 - Phenethyl isothiocyanate sensitizes glioma cells to TRAIL-induced apoptosis.
Lee DH, Kim DW, Lee HC, Lee JH, Lee TH. Lee DH, et al. Biochem Biophys Res Commun. 2014 Apr 18;446(4):815-21. doi: 10.1016/j.bbrc.2014.01.112. Epub 2014 Jan 31. Biochem Biophys Res Commun. 2014. PMID: 24491546 - NVP-BKM120 potentiates apoptosis in tumor necrosis factor-related apoptosis-inducing ligand-resistant glioma cell lines via upregulation of Noxa and death receptor 5.
Foster KA, Jane EP, Premkumar DR, Morales A, Pollack IF. Foster KA, et al. Int J Oncol. 2015 Aug;47(2):506-16. doi: 10.3892/ijo.2015.3035. Epub 2015 Jun 5. Int J Oncol. 2015. PMID: 26044191 Free PMC article. - Lessons from TRAIL-resistance mechanisms in colorectal cancer cells: paving the road to patient-tailored therapy.
Van Geelen CM, de Vries EG, de Jong S. Van Geelen CM, et al. Drug Resist Updat. 2004 Dec;7(6):345-58. doi: 10.1016/j.drup.2004.11.002. Epub 2005 Jan 8. Drug Resist Updat. 2004. PMID: 15790545 Review. - Targeting Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL): A Promising Therapeutic Strategy in Gliomas.
Alexiou GA, Tsamis KI, Kyritsis AP. Alexiou GA, et al. Semin Pediatr Neurol. 2015 Mar;22(1):35-9. doi: 10.1016/j.spen.2014.12.002. Epub 2014 Dec 11. Semin Pediatr Neurol. 2015. PMID: 25976259 Review.
Cited by
- Knockdown of apoptosis repressor with caspase recruitment domain (ARC) increases the sensitivity of human glioma cell line U251MG to VM-26.
Wang Q, Li A, Wang H, Wang J. Wang Q, et al. Int J Clin Exp Pathol. 2012;5(6):555-61. Epub 2012 Jul 29. Int J Clin Exp Pathol. 2012. PMID: 22949938 Free PMC article. - Long non-coding RNAs in anti-cancer drug resistance.
Chen QN, Wei CC, Wang ZX, Sun M. Chen QN, et al. Oncotarget. 2017 Jan 3;8(1):1925-1936. doi: 10.18632/oncotarget.12461. Oncotarget. 2017. PMID: 27713133 Free PMC article. Review. - Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma.
Van Meir EG, Hadjipanayis CG, Norden AD, Shu HK, Wen PY, Olson JJ. Van Meir EG, et al. CA Cancer J Clin. 2010 May-Jun;60(3):166-93. doi: 10.3322/caac.20069. CA Cancer J Clin. 2010. PMID: 20445000 Free PMC article. Review. - TSPO acts as an immune resistance gene involved in the T cell mediated immune control of glioblastoma.
Menevse AN, Ammer LM, Vollmann-Zwerenz A, Kupczyk M, Lorenz J, Weidner L, Hussein A, Sax J, Mühlbauer J, Heuschneider N, Rohrmus C, Mai LS, Jachnik B, Stamova S, Volpin V, Durst FC, Sorrentino A, Xydia M, Milenkovic VM, Bader S, Braun FK, Wetzel C, Albert NL, Tonn JC, Bartenstein P, Proescholdt M, Schmidt NO, Linker RA, Riemenschneider MJ, Beckhove P, Hau P. Menevse AN, et al. Acta Neuropathol Commun. 2023 May 8;11(1):75. doi: 10.1186/s40478-023-01550-9. Acta Neuropathol Commun. 2023. PMID: 37158962 Free PMC article. - A Chimeric Signal Peptide-Galectin-3 Conjugate Induces Glycosylation-Dependent Cancer Cell-Specific Apoptosis.
Lee SH, Khwaja Rehman F, Tyler KC, Yu B, Zhang Z, Osuka S, Zerrouqi A, Kaluzova M, Hadjipanayis CG, Cummings RD, Olson JJ, Devi NS, Van Meir EG. Lee SH, et al. Clin Cancer Res. 2020 Jun 1;26(11):2711-2724. doi: 10.1158/1078-0432.CCR-18-3280. Epub 2020 Jan 22. Clin Cancer Res. 2020. PMID: 31969339 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical